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induced tumor formation in gene target-
ed or transgenic mice might provide
insights relevant to human carcinogene-
sis. An instructive and relevant parallel to
the current findings was the initial excite-
ment generated by several papers that
described FasL expression on tumors.
FasL, a member of the TNF family of pro-
apoptotic molecules, can induce the
death of cells that express the cognate
death ligand Fas.Theoretically, this could
lead to T cell deletion and “immune privi-
lege” status for the tumor. The resulting
predictions that FasL overexpression on
tissue allografts would delay or prevent
rejection were not fulfilled. In fact,
implantation of FasL-overexpressing
cells in mice resulted in precisely the
opposite result: even more rapid rejec-
tion and abscess formation in the trans-
planted tissue (reviewed in Restifo,
2000).
Along with the present report of
Dong and collaborators, the literature
currently contains several others postu-
lating or purporting to show inhibition of
T cell effector function as a result of
interaction with cancer cells (Figure 2).
These reports include models where
cancer cells may (i) overexpress serpins
(protease inhibitors) that block granzyme
B-mediated apoptosis (Medema et al.,
2001); (ii) downregulate expression of
purported granzyme receptors such as
the 280 kDa mannose-6-phosphate
receptor (Motyka et al., 2001), also
blocking apoptosis; or (iii) transmit a sig-
nal to cytotoxic T lymphocytes that
blocks the PI-3 kinase pathway, leading
to failure of perforin and granzyme
secretion due to dysregulated granule
trafficking (Radoja et al., 2001). Each of
these hypotheses requires further test-
ing in appropriate animal models, and
extreme caution is essential before
applying the apparently logical conse-
quences of these “lessons” to human
cancer therapy.
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salvador—The persistence of proliferation
Despite years of extensive studies on genes that regulate proliferation and cell death, two processes that must be tightly
coordinated throughout development to regulate cell number, remarkably few genes have been shown to affect both
processes. Using an elegant genetic screen in the fly eye,Tapon et al. (2002) have identified a gene, salvador, which is espe-
cially significant, because it not only regulates and coordinates both exit from the cell cycle and apoptosis, but also has a
human homolog that may play a key role in tumorigenesis.
The fly eye develops from merely 30 prog-
enitor cells into an exquisitely precise and
highly ordered structure consisting of
approximately 800 individual units or
ommatidia and numbering more than
15,000 cells. To reach this final form,
which is so beautifully regular that it has
been called a “neurocrystalline lattice”
(Ready et al., 1976), the signals for prolif-
eration, patterning, exit from the cell
cycle, differentiation, and cell death all
must be carefully regulated and coordi-
nated. The fly eye has provided a sensi-
tive system for the discovery of genes and
regulatory networks that control these
processes, but noticeably, few genes have
been shown to regulate both exit from the
cell cycle and execution of the apoptotic
program—two developmental events that
must be tightly coordinated to regulate
cell number. When these processes are
uncoupled or disrupted, the host is at risk
for developing a tumor.
Tumor suppressors are genes that,
when inactivated, confer a proliferative
advantage over normal cells. This can
occur by a variety of different mecha-
nisms and can lead to the development of
tumors, disorganized masses of tissue
that can cause the death of the host—
whether that host is a fruit fly (Woodhouse
et al., 1998) or a human being. In fact,
many, if not all, human cancers involve 
the inactivation of tumor suppressors
(Hanahan and Weinberg, 2000). These
genes comprise an important and diverse
group, and their discovery and characteri-
zation have helped us develop a deeper
understanding of cancer cell biology. To
date, a large number of tumor suppressor
genes have been reported in flies, and
many of them have human homologs that
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have been implicated in tumorigenesis
(Huang et al., 1999; Potter et al., 2001;
Tapon et al., 2001).
In 1995, Xu et al. described a power-
ful screen to use the then recently devel-
oped technique of mitotic recombination
using Flp-recombinase in the fly eye as a
means to discover new tumor suppressor
genes (Xu et al., 1995). By inducing
mitotic clones early in eye development
and comparing the size of the resulting
mutant clones with their wild-type coun-
terparts, the researchers were able to
isolate mutations which conferred a
growth advantage to the mutant tissue
and even caused cancer-like masses to
appear in the fly. The authors of a recent
paper in Cell (Tapon et al., 2002) con-
ducted a similar screen that has identified
mutations in several tumor suppressors
and negative regulators of proliferation.
They now report the characterization of
an interesting gene they have named sal-
vador (sav) after the surrealist painter
Salvador Dalí, who once claimed (before
his death) to be immortal.
In normal retinal development, prog-
enitor cells proliferate early and are later
patterned and recruited sequentially to
adopt the various cell fates and form
ommatidia, the individual light-sensing
structures of the compound eye that are
made of photoreceptors and supporting
cells.The last cells recruited into the final
structure become interommatidial cells,
cells that normally form a single layer
between ommatidia, leaving an excess
of approximately 2000 cells which are
then pruned during a period of apopto-
sis.This cell death results in a tight lattice
of interommatidial cells. Cells mutant for
sav are at a proliferative advantage over
their wild-type counterparts. When a
mitotic clone is induced early in eye
development to generate a sav mutant
cell and a wild-type cell, the mutant one
eventually contributes more cells to the
fully developed eye. Upon sectioning the
eye, one sees that while ommatidial pat-
terning is generally unaffected, the
mutant tissue contains many more
interommatidial cells, suggestive of a
defect in cell death. In clones of the most
severe sav allele, sav3, the mutant tissue
protrudes out in folds. In addition, when
sav3 clones are induced in other parts of
the body, mutant tissue develops into
tumorous growths.
How does loss of sav lead to such a
phenotype? First, BrdU labeling experi-
ments in the developing eye demon-
strate that mutant cells continue to prolif-
erate for 12 to 24 hr after their wild-type
counterparts have exited the cell cycle
and begun to differentiate. The mutant
cells have elevated levels of CyclinE
RNA and protein, a condition that pre-
vents exit from the cell cycle. Thus, one
function of sav is to reduce CyclinE lev-
els, at least in part by regulating its tran-
scription. Eventually, however, the
mutant cells do stop dividing, presum-
ably because other mechanisms are at
work to inhibit CyclinE.
The next defect that is apparent in
sav mutant tissue is a dramatic reduction
in cell death in the interommatidial cells;
at a point when there is widespread cell
death in wild-type tissue, mutant cells do
not die. Protein levels (but not RNA lev-
els) of a key regulator of cell death,
DIAP1 (Drosophila inhibitor of apoptosis
1), are elevated, suggesting that inc-
reased levels of DIAP1 in sav clones,
caused by a transcriptionally indepen-
dent mechanism, may overcome proapo-
ptotic signals. Indeed, overexpression of
Reaper or Hid, two potent proapoptotic
proteins that normally inhibit DIAP1 by
binding to it and targeting it for degrada-
tion (Martin, 2002), fails to have an effect
in tissue mutant for sav. Notably, an
especially potent form of Hid that is
resistant to inactivation by phosphoryla-
tion, Hid-Ala5, can overcome the elevat-
ed DIAP1 levels and still induce some
cell death in sav clones. This indicates
that sav is not absolutely required for
apoptosis to occur and that sav may nor-
mally function to downregulate basal
DIAP1 levels posttranscriptionally.
The Sav protein is 608 amino acids
long with two putative WW domains and
a C-terminal coiled-coil region. It is
expressed in the developing eye in
regions where cells are arrested in the
cell cycle. salvador is also expressed in
other tissues, for mutant sav clones in
the notum and the haltere also cause
tumors. Interestingly, the region of Sav
containing the WW domains can bind in
vitro to a serine-threonine kinase called
Warts/LATS, another tumor suppressor
whose phenotype overlaps substantially
with that of sav but is somewhat more
severe (Justice et al., 1995; Xu et al.,
1995). Mutant clones of warts also devel-
op into tumors, contain extra interomma-
tidial cells, display increased levels of
CyclinE, and show almost no apoptosis.
(Significantly, mice lacking a homolog of
Warts, LATS1, develop hyperplasia and
tumors in several tissues [St John et al.,
1999]. Additionally, a recent report indi-
cates that human LATS1 regulates both
the cell cycle and cell death [Xia et al.,
2002].) Warts and Sav may work togeth-
er synergistically, since overexpression
of either Sav or Warts in the fly eye caus-
es very subtle or no defects, yet simulta-
neous overexpression of both induces
broad cell death and causes the eye to
be considerably smaller. However,
despite this interaction and the finding
that the proteins can associate in vitro,
the two genes are not in a linear path-
way; the double mutant phenotype is
more severe than either single mutant
phenotype. Thus, questions remain
about the relationship of Sav and Warts.
sav is widely conserved with
homologs in worms and mammals. Also,
the human sav ortholog, hWW45, maps
to a genomic region subject to allelic loss
in several different cancers in a variety of
tissues (Valverde, 2000). Because of
this, the authors tested whether hWW45
is mutated in cancer cell lines. After ana-
lyzing cell lines derived from multiple tis-
sues, they found that two renal cell carci-
noma cell lines, ACHN and 786-O, both
have homozygous deletions in hWW45.
Even more suggestive, these deletions
overlap in only a 21 kB region, a seg-
ment that apparently contains only exons
3–5 of hWW45 and no other transcrip-
tional units. Since hWW45 is ubiquitously
expressed in adult tissues (Valverde,
2000), perhaps further studies will reveal
that the gene is involved in other cancers
as well.
As any interesting study does, this
paper raises some questions. First, an
important question about the sav mutant
phenotype remains unanswered. The
authors elegantly demonstrate a role for
sav in regulating both cell cycle exit and
apoptosis, two findings that explain one
aspect of the mutant phenotype: the
excess of interommatidial cells. However,
there is another important aspect to the
phenotype of sav mutant clones. These
clones have considerably more omma-
tidia than their wild-type counterparts,
indicating that the loss of sav provides
mutant cells with a proliferative advan-
tage. Do sav mutant clones have a short-
er or quicker cell cycle, or do they just
proceed through an extra division or two?
The authors did not detect a gross differ-
ence in cell cycle parameters, but they
point out that even a very subtle differ-
ence undetectable by their assays would
be amplified over several cell cycles to
cause an obvious size discrepancy
between mutant and wild-type clones.
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How does sav confer such a growth
advantage?
Furthermore, several questions per-
sist about sav’s mechanism of action.
First, although sav clearly affects tran-
scriptional levels of CyclinE, how is the
signal transduced to the nucleus and
integrated with other transcriptional regu-
lators of CyclinE? Also, how exactly does
Sav keep DIAP1 levels down in a tran-
scriptionally independent way? Finding in
vivo binding partners of Sav will probably
help answer these questions.
Knowledge of such binding partners
may shed light on some other important
questions and help fit sav into a path-
way (or several pathways). For example,
is sav in fact part of the Reaper/Hid
pathway, or is it involved in a parallel
pathway? Might sav even play a direct
role in helping Hid and Reaper target
DIAP1 for degradation? Also, what is
the relationship between sav and the
MAPK pathway, a group of genes that
also regulates both the cell cycle and
apoptosis?
Finally, the sav study raises several
cancer-related questions. For instance,
can the transformed phenotype of the
hWW45 null cell lines be attributed to the
lack of that gene? Can sav’s role in
tumorigenesis in the mammal be demon-
strated in vivo; i.e., will a tissue-specific
knockout of the mouse sav/hWW45
homolog, mWW45, induce the develop-
ment of tumors in that tissue? If so, will
they be capable of metastatic growth, or
will the cells behave as in the fly, terminal-
ly differentiating and remaining in situ?
Ultimately, we would like to know if muta-
tions in hWW45 cause tumors in humans.
Clearly, the discovery of sav is an
exciting one. Hopefully, salvador can paint
us a clearer picture of tumorigenesis.
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